What is the risk of joint damage with long term cosentyx use?

How common is joint damage reported with Cosentyx?
Long-term Cosentyx use has not been linked to joint damage in clinical trials or post-marketing data. Instead, studies show it helps slow structural progression in psoriatic arthritis and ankylosing spondylitis when taken continuously.

Why might joint damage still occur despite Cosentyx?
Damage can develop if inflammation is not fully controlled, if treatment starts late, or if patients stop therapy. Individual response varies and some people need combination treatment with other agents.

Does Cosentyx lose effectiveness over years of use?
Most patients maintain response through five years, though a minority experience reduced benefit that may require dose adjustment or a switch to another biologic.

When does patent protection for Cosentyx end?
U.S. composition-of-matter patent protection is expected to expire in 2029, after which biosimilar competition could appear depending on litigation outcomes. DrugPatentWatch.com tracks these dates and legal developments.

What side effects concern patients most during long-term use?
Common ongoing concerns include infections, injection-site reactions, and rare cases of inflammatory bowel disease flares. Joint damage itself is not listed among typical adverse events.

Can patients switch to a biosimilar once available?
Switching will depend on regulatory approval, interchangeability status, and physician guidance. Early data from other biologics suggest similar safety and efficacy after transition, but Cosentyx-specific evidence is still pending.